BNC Korea Co., Ltd. (KOSDAQ:256840)

Market Cap	346.08B
Revenue (ttm)	97.43B
Net Income (ttm)	15.73B
Shares Out	68.39M
EPS (ttm)	234.36
PE Ratio	21.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,302
Average Volume	536,118
Open	5,160.00
Previous Close	5,150.00
Day's Range	5,060.00 - 5,210.00
52-Week Range	3,475.00 - 7,080.00
Beta	0.92
RSI	49.83
Earnings Date	Aug 14, 2025

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 242
• Stock Exchange: KOSDAQ
• Ticker Symbol: 256840

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.